参考文献/References:
[1]Stein PD,Hull RD,Patel KC,et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism:a systematic review[J]. Ann Intern Med,2004,140(8):589-602.
[2] Hull RD, Patel KC, Olson RE, et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism:a systematic review[J]. Ann Intern Med,2004,140(8):589-602.
[3]Konstantinides SV,Torbicki A,Agnelli G,et al,2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism[J]. Eur Heart J,2014,35(43):3033-3069.
[4]中华医学会呼吸病学分会肺栓塞与肺血管病学组. 肺血栓栓塞症诊治与预防指南.中华医学杂志2018,98(14):1060-1087.
[5]Carrier M,Righini M,Djurabi RK,et al. VIDAS D-dimer in combination with clinical pre-test probability to rule out pulmonary embolism. A systematic review of management outcome studies[J]. Thromb Haemost,2009,101(5):886-892.
[6]Righini M, van Es J, Den Exter PL, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study[J]. JAMA,2014,311(11):1117-1124.
[7]van der Pol LM, Mairuhu AT, Tromeur C, et al. Use of clinical prediction rules and D-dimer tests in the diagnostic management of pregnant patients with suspected acute pulmonary embolism[J]. Blood Rev,2017,31(2):31-36.
[8]de Lemos JA,McGuire DK,Drazner MH,et al. B-type natriuretic peptide in cardiovascular disease[J]. Lancet (London, England),2003,362(9380):316-322.
[9]Henzler T,Roeger S,Meyer M,et al. Pulmonary embolism: CT signs and cardiac biomarkers for predicting right ventricular dysfunction[J]. Eur Respir J,2012,39(4):919-926.
[10]Agterof MJ, Schutgens RE, Snijder RJ, et al. Out of hospital treatment of acute pulmonary embolism in patients with a low NT-proBNP level[J]. J Thromb Haemost,2010,8(6):1235-1241.
[11]Klok FA, Mos IC, Huisman MV. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism:a systematic review and meta-analysis[J]. Am J Respir Crit Care Med,2008,178(4):425-430.
[12]Binder L,Pieske B,Olschewski M,et al. N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism[J]. Circulation,2005,112(11):1573-1579.
[13]Lankeit M,Jimenez D,Kostrubiec M,et al. Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism[J]. Eur Respir J,2014,43(6):1669-1677.
[14]Katrukha IA. Human cardiac troponin complex. Structure and functions[J]. Biochemistry(Mosc),2013,78(13):1447-1465.
[15]Westermann D,Neumann JT,Sorensen NA,et al. High-sensitivity assays for troponin in patients with cardiac disease[J]. Nat Rev Cardiol,2017,14(8):472-483.
[16]Jimenez D,Uresandi F,Otero R,et al. Troponin-based risk stratification of patients with acute nonmassive pulmonary embolism:systematic review and metaanalysis[J]. Chest,2009,136(4):974-982.
[17]Bajaj A,Saleeb M,Rathor P,et al. Prognostic value of troponins in acute nonmassive pulmonary embolism:a meta-analysis[J]. Heart Lung,2015,44(4):327-334.
[18]Lankeit M,Friesen D,Aschoff J,et al. Highly sensitive troponin T assay in normotensive patients with acute pulmonary embolism[J]. Eur Heart J,2010,31(15):1836-1844.
[19] Konstantinides SV,Meyer G,Lang I,et al.Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: rationale and design of the Pulmonary Embolism Thrombolysis(PEITHO) trial[J]. Am Heart J,2012,163(1):33-38.e31.
[20]Meyer G,Planquette B,Sanchez O. Fibrinolysis for acute care of pulmonary embolism in the intermediate risk patient[J]. Curr Atheroscler Rep,2015,17(12):68.
[21]Otaki Y, Watanabe T, Kubota I. Heart-type fatty acid-binding protein in cardiovascular disease: a systemic review[J]. Clin Chim Acta,2017,474: 44-53.
[22]Dellas C, Puls M, Lankeit M, et al. Elevated heart-type fatty acid-binding protein levels on admission predict an adverse outcome in normotensive patients with acute pulmonary embolism[J]. J Am Coll Cardiol,2010,55(19):2150-2157.
[23]Lankeit M, Friesen D, Schafer K, et al. A simple score for rapid risk assessment of non-high-risk pulmonary embolism[J]. Clin Res Cardiol,2013,102(1):73-80.
[24]Xiao J, Jing ZC, Ellinor PT, et al. MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism[J]. J Transl Med,2011,9:159.
[25]Zhou X, Wen W, Shan X, et al. MiR-28-3p as a potential plasma marker in diagnosis of pulmonary embolism[J]. Thromb Res,2016,138:91-95.
[26]Kessler T, Erdmann J, Vilne B, et al. Serum microRNA-1233 is a specific biomarker for diagnosing acute pulmonary embolism[J]. J Transl Med,2016,14(1): 120.
[27]Qin J, Liang H, Shi D, et al. A panel of microRNAs as a new biomarkers for the detection of deep vein thrombosis[J]. J Thromb Thrombolysis,2015,39(2):215-221.
[28]Deng HY, Li G, Luo J, et al. MicroRNAs are novel non-invasive diagnostic biomarkers for pulmonary embolism:a meta-analysis[J]. J Thorac Dis,2016,8(12): 3580-3587.
[29]Kempf T, Wollert KC. Growth differentiation factor-15: a new biomarker in cardiovascular disease[J]. Herz,2009,34(8):594-599.
[30]Lankeit M, Kempf T, Dellas C, et al. Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism[J]. Am J Respir Crit Care Med,2008,177(9):1018-1025.
[31]Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity[J]. Nat Rev Immunol,2013,13(1):34-45.
[32]Kayrak M, Erdogan HI, Solak Y, et al. Prognostic value of neutrophil to lymphocyte ratio in patients with acute pulmonary embolism: a restrospective study[J]. Heart Lung Circ,2014,23(1):56-62.
[33]Bhat TM, Afari ME, Garcia LA. Neutrophil lymphocyte ratio in peripheral vascular disease: a review[J]. Expert Rev Cardiovasc Ther,2016,14(7):871-875.
[34]Galliazzo S, Nigro O, Bertu L, et al. Prognostic role of neutrophils to lymphocytes ratio in patients with acute pulmonary embolism:a systematic review and meta-analysis of the literature[J]. Intern Emerg Med,2018,13(4):603-608.
[35]Akgullu C, Omurlu IK, Eryilmaz U, et al. Predictors of early death in patients with acute pulmonary embolism[J]. Am J Emerg Med,2015,33(2):214-221.
[36]Kline JA, Zeitouni R, Marchick MR, et al. Comparison of 8 biomarkers for prediction of right ventricular hypokinesis 6 months after submassive pulmonary embolism[J]. Am Heart J,2008,156(2):308-314.
[37]Abul Y,Karakurt S,Ozben B,et al. C-reactive protein in acute pulmonary embolism[J]. J Investig Med,2011,59(1):8-14.
[38]Araz O, Yilmazel Ucar E, Yalcin A, et al. Predictive value of serum Hs-CRP levels for outcomes of pulmonary embolism[J]. Clin Respir J,2016,10(2):163-167.
[39]Ozsu S, Abul Y, Gunaydin S, et al. Prognostic value of red cell distribution width in patients with pulmonary embolism[J]. Clin Appl Thromb Hemost,2014,20(4):365-370.
[40]Abul Y, Ozsu S, Korkmaz A, et al. Red cell distribution width: a new predictor for chronic thromboembolic pulmonary hypertension after pulmonary embolism[J]. Chron Respir Dis,2014,11(2):73-81.
[41]Celik A, Ozcan IT, Gundes A, et al. Usefulness of admission hematologic parameters as diagnostic tools in acute pulmonary embolism[J]. Kaohsiung J Med Sci,2015,31(3):145-149.
[42]Scherz N, Labarere J, Mean M,et al. Prognostic importance of hyponatremia in patients with acute pulmonary embolism[J]. Am J Respir Crit Care Med,2010,182(9): 1178-1183.
[43]Ng AC,Chow V,Yong AS,et al. Fluctuation of serum sodium and its impact on short and long-term mortality following acute pulmonary embolism[J]. PLoS One,2013,8(4):e61966.
[44]Turedi S, Gunduz A, Mentese A, et al. Value of ischemia-modified albumin in the diagnosis of pulmonary embolism[J]. Am J Emerg Med,2007,25(7):770-773.
[45]Topuz M, Kaplan M, Akkus O, et al. The prognostic importance of thiol/disulfide homeostasis in patients with acute pulmonary thromboembolism[J]. Am J Emerg Med, 2016,34(12):2315-2319.
[46]Scherz N, Labarere J, Aujesky D, et al. Elevated admission glucose and mortality in patients with acute pulmonary embolism[J]. Diabetes Care,2012,35(1):25-31.
[47]Zorlu A, Yucel H, Bektasoglu G, et al. Increased gamma-glutamyl transferase levels predict early mortality in patients with acute pulmonary embolism[J]. Am J Emerg Med,2012,30(6):908-915.
相似文献/References:
[1]郭君君,郑宏超,曹阳.生物标志物对急性心肌梗死介入治疗预后的预测意义[J].心血管病学进展,2016,(1):37.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.010]
GUO Junjun,ZHENG Hongchao,CAO Yang.Prognostic Significance of Biomarkers in Predicting Acute Myocardial
Infarction after Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2016,(5):37.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.010]
[2]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(5):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[3]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(5):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[4]刘壮壮 黄宇理.心力衰竭生物标志物的研究进展[J].心血管病学进展,2020,(1):67.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.018]
LIU Zhuangzhuang,HUANG Yuli.Biomarkers for Heart Failure[J].Advances in Cardiovascular Diseases,2020,(5):67.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.018]
[5]王同霞 陈章荣.可溶ST2与心力衰竭患者预后的评价[J].心血管病学进展,2020,(5):495.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.013]
WANG Tongxia,CHEN Zhangrong.Prognosis of Heart Failure Patients and Soluble ST2[J].Advances in Cardiovascular Diseases,2020,(5):495.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.013]
[6]冯小梅 李彦红.Ⅰ型前胶原羧基端肽和Ⅲ型前胶原氨基端肽在心肌纤维化的研究进展[J].心血管病学进展,2020,(5):517.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.018]
FENG Xiaomei,LI Yanhong.PCP and PNP in Myocardial Fibrosis[J].Advances in Cardiovascular Diseases,2020,(5):517.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.018]
[7]李谧 李琳.生长分化因子-15在心房颤动中的研究及应用进展[J].心血管病学进展,2020,(7):749.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.0 19]
LI Mi,LI Lin.Research and Application of Growth Differentiation Factor-15 in Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(5):749.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.0 19]
[8]于博文 修成奎 王雪 杨静 雷燕.内皮微粒在临床中的研究进展及应用[J].心血管病学进展,2021,(1):76.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
YU Bowen,XIU Chengkui,WANG Xue,et al.Research Progress and Application of Endothelial Microparticles in Clinic[J].Advances in Cardiovascular Diseases,2021,(5):76.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
[9]刘月娥 关秀茹.循环miRNA作为冠心病潜在生物标志物的研究进展[J].心血管病学进展,2021,(2):171.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.019]
LIU Yuee,GUAN Xiuru.Research Progress of Circulating Mirna as a Potential Biomarker of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2021,(5):171.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.019]
[10]孙悦宁 富路.左心室逆重构在心力衰竭中的研究新进展[J].心血管病学进展,2021,(6):525.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.012]
SUN Yuening,FU Lu.Research Progress of Left Ventricular Reverse Remodeling in Heart Failure[J].Advances in Cardiovascular Diseases,2021,(5):525.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.012]